Cell Proliferation, Cell Cycle Abnormalities, and Cancer Outcome in Patients with Barrett's Esophagus: A Long-term Prospective Study
Open Access
- 1 November 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (21) , 6988-6995
- https://doi.org/10.1158/1078-0432.ccr-07-5063
Abstract
Purpose: Elevated cellular proliferation and cell cycle abnormalities, which have been associated with premalignant lesions, may be caused by inactivation of tumor suppressor genes. We measured proliferative and cell cycle fractions of biopsies from a cohort of patients with Barrett's esophagus to better understand the role of proliferation in early neoplastic progression and the association between cell cycle dysregulation and tumor suppressor gene inactivation. Experimental Design: Cell proliferative fractions (determined by Ki67/DNA multiparameter flow cytometry) and cell cycle fractions (DNA content flow cytometry) were measured in 853 diploid biopsies from 362 patients with Barrett's esophagus. The inactivation status of CDKN2A and TP53 was assessed in a subset of these biopsies in a cross-sectional study. A prospective study followed 276 of the patients without detectable aneuploidy for an average of 6.3 years with esophageal adenocarcinoma as an end point. Results: Diploid S and 4N (G2/tetraploid) fractions were significantly higher in biopsies with TP53 mutation and loss of heterozygosity. CDKN2A inactivation was not associated with higher Ki67-positive, diploid S, G1, or 4N fractions. High Ki67-positive and G1-phase fractions were not associated with the future development of esophageal adenocarcinoma (P = 0.13 and P = 0.15, respectively), whereas high diploid S-phase and 4N fractions were (P = 0.03 and P < 0.0001, respectively). Conclusions: High Ki67-positive proliferative fractions were not associated with inactivation of CDKN2A and TP53 or future development of cancer in our cohort of patients with Barrett's esophagus. Biallelic inactivation of TP53 was associated with elevated 4N fractions, which have been associated with the future development of esophageal adenocarcinoma.Keywords
This publication has 63 references indexed in Scilit:
- Limiting the Proliferation of Polyploid CellsCell, 2007
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal AdenocarcinomaPLoS Medicine, 2007
- Cyclin A Immunocytology as a Risk Stratification Tool for Barrett's Esophagus SurveillanceClinical Cancer Research, 2007
- Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence baseBMJ, 2006
- High grade dysplasia still is not an indication for surgery in patients with Barrett's esophagus: An updateGastroenterology, 1998
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53Published by Elsevier ,1992
- Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 allelesCell, 1992
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971